Sokal Score = exp (0.0116 x (age [years] – 43.4)) + (0.0345 x (spleen size [cm] – 7.51) + (0.188 x ((platelets [109/L]/700)2 – 0.563)) + (0.0887 x (blasts [%] – 2.10))
Facts & Figures
Based on analysis of survival of 813 patients diagnosed with chronic phase CML between 1962 and 1981. Most patients were treated with single-agent chemotherapy, typically busulfan.
|Risk Group||Sokal Score||2 year Survival||Median Survival time|
|Intermediate||0.8 - 1.2||65-90%||2.5-5 years|
Original/Primary ReferenceSokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood 1984; 63: 789-99.
About the Creator
Joseph E. Sokal, MD, (d. 1988) was a researcher in cancer treatment and a scholar in residence at Duke University. Previously, he was chief cancer research clinician at Roswell Park Memorial Institute in Buffalo and an assistant professor at Yale University.
To view Dr. Joseph E. Sokal's publications, visit PubMed